Clinical Trials Logo

Emphysema or COPD clinical trials

View clinical trials related to Emphysema or COPD.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04520152 Completed - Emphysema or COPD Clinical Trials

Evaluation of the Free Flow Medical Lung Tensioning Device System for the Treatment of Severe Emphysema

EFFORT
Start date: June 23, 2021
Phase: N/A
Study type: Interventional

Patients with severe emphysema have limited options for treatment. Current treatments include lung transplant, lung volume reduction surgery or endobronchial lung volume reduction using valves or coils. These options are only available for a small and selected group of patients. The Free Flow Medical Lung Tensioning Device System (LTD) is thought to be the next generation endobronchial treatment for patients with severe emphysema designed to address this unmet need. The LTD is designed to compress the areas of lung parenchyma most damaged by emphysema and to tension surrounding tissue to help restore lung elastic recoil in a similar manner to the lung volume reduction coils.

NCT ID: NCT03679598 Completed - Emphysema or COPD Clinical Trials

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

ATALANTa
Start date: April 8, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, double-blind, randomized (1:1), placebo-controlled, 12-week, proof-of-concept study to evaluate the safety and tolerability as well as the mechanistic effect of oral administration of alvelestat (MPH966) in subjects with confirmed AATD defined as Pi*ZZ, Pi*SZ, Pi*null, or another rare phenotype/genotype known to be associated with either low (serum AAT level <11 μM or <57.2 mg/dL) or functionally impaired AAT including "F" or "I" mutations.

NCT ID: NCT03670121 Completed - Emphysema or COPD Clinical Trials

A Pilot Study to Assess Treatment of Patients With Homogeneous Emphysema Using Sequential Segmental Bronchoscopic Thermal Vapor Ablation (NEXT STEP)

NEXT STEP
Start date: August 28, 2018
Phase: N/A
Study type: Interventional

This study is a Prospective, single arm, single center pilot study following outcomes for 12 months after initial BTVA treatment. The primary objectives of the study are to prospectively document the safety and efficacy of sequential segmental treatment with BTVA in patients with a homogeneous distribution of emphysema that are not candidates for endobronchial valve therapy.

NCT ID: NCT03205826 Completed - Emphysema or COPD Clinical Trials

Chartis Collateral Ventilation Measurement: Conscious Sedation Versus General Anesthesia

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

Rationale: The Chartis® ( Pulmonx, CA, USA) measurement system is a tool to assess interlobar collateral ventilation during bronchoscopy. Assessing collateral ventilation is important when you intend to treat a patient with endobronchial valves. Chartis measurement of collateral ventilation can be performed under both conscious sedation as well as general anesthesia. There is no consensus on what is the preferred method of anesthesia for Chartis measurements in the literature. Objective: In this project we want to investigate whether there is a difference in Chartis measurement outcomes between these two methods of anesthesia: conscious sedation and general anesthesia. Study design: This study will be a single center observational study Study population: The study population exists of patients with severe emphysema who undergo collateral ventilation assessment before bronchoscopic lung volume reduction treatment with one-way endobronchial valves. Intervention: All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia. Main study parameters/endpoints: Our primary outcome measure is the failure rate of the Chartis collateral ventilation measurement under general anesthesia versus conscious sedation.